Effects of pindolol on serum lipids, apolipoproteins, and lipoproteins in patients with mild to moderate essential hypertension.
The effects of 12 weeks' administration of the beta-blocker pindolol (5 mg twice daily) on serum lipids, apolipoproteins (apo), and lipoproteins were studied in 20 normolipidemic patients with mild to moderate essential hypertension (WHO I-II). Pindolol significantly increased both high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C), while very-low-density lipoprotein cholesterol (VLDL-C) was significantly decreased. Apo A-II levels were increased significantly and the apo B/apo A-I ratio, which is one of the atherogenic indexes, was decreased significantly after pindolol therapy. Total cholesterol, HDL subfraction cholesterols, the LDL-C/HDL-C ratio, triglycerides, apo A-I, apo B, apo C-II, apo C-III, and apo E did not change significantly.
Sasaki
J
J
Department of Internal Medicine, Fukuoka University Hospital, Japan.
Saku
K
K
Ideishi
M
M
Arakawa
K
K
Kato
Y
Y
Kuwano
E
E
So
T
T
D000328:Adult; D000368:Aged; D001053:Apolipoproteins / Q000097:blood*; D001794:Blood Pressure / Q000187:drug effects; D008078:Cholesterol, LDL / Q000097:blood; D015243:Cholesterol, VLDL / Q000097:blood; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010869:Pindolol / Q000009:adverse effects* / Q000627:therapeutic use; D011674:Pulse / Q000187:drug effects
D001053:Apolipoproteins; D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D008055:Lipids; D008074:Lipoproteins; D010869:Pindolol